Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab-Hyaluronidase for Relapsed/Refractory MRD in T-ALL
NCT05289687Phase 2Recruiting
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- May 2023
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Darzalex Faspro in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Complete Remission at Day 64, Complete Response with Partial Count Recovery at Day 64 and 5 more. Started May 2023; status: recruiting.
02
Drugs
Darzalex Faspro
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT05289687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289687.